Category: Q1Syndicate content

Pharma the lone Q1 bright spot for J&J

April 14, 2015 by Brad Perriello

The strong dollar pares a 13% chunk out Johnson & Johnson's 1st-quarter sales, prompting a lowered earnings outlook, but the healthcare giant still manages to beat Wall Street's estimate.

Pharma the lone bright spot for J&J's Q1 sales

EmboMedics deal gets AngioDynamics back into embolization

April 10, 2015 by Brad Perriello

AngioDynamics, which reported declining fiscal 3rd-quarter sales and earnings, said it's getting back into embolization with a licensing deal for EmboMedics' microspheres.

EmboMedics deal gets AngioDynamics back into embolization

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Biomet swings to Q3 black

April 9, 2015 by Brad Perriello

Biomet reports a swing to fiscal 3rd-quarter profits despite a top-line dip due to foreign currency rates.

Biomet swings to Q3 black

Biomet today reported a return to fiscal 3rd-quarter profits, despite a foreign currency hit that pushed its top line down nearly 3%, in what's likely its last financial release as an independent company.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Edwards settlement slashes Medtronic's Q4 profits

May 20, 2014 by Brad Perriello

Medtronic's 4th-quarter profits plunged nearly 54% on its $750 million settlement with Edwards Lifesciences over replacement heart valve technology.

Edwards settlement slashes Medtronic's Q4 profits

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Thoratec: NEJM article cost us market share

May 7, 2014 by Brad Perriello

A New England Journal of Medicine report on higher-than-expected blood clot rates for Thoratec's HeartMate II implantable heart pump took market share during the 1st quarter, company officials said today.

Thoratec: NEJM article cost us market share

A New England Journal of Medicine report last year detailing sharp increases in the rate of blood clots helped take market share away from Thoratec (NSDQ:THOR) and its HeartMate II implantable heart pump, company officials said yesterday.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Is Siemens Healthcare headed for a spinout?

May 7, 2014 by Brad Perriello

A massive restructuring at Siemens aims to establish its healthcare business, which posted fiscal 2nd-quarter profit growth of 19%, as a stand-alone division could be the 1st step toward a spinout for Siemens Healthcare.

Is Siemens Healthcare headed for a spinout?

Siemens (NYSE:SI) unveiled a massive reorganization today that could be the 1st step toward a spinout for its healthcare business, which posted 19% profit growth during Siemens' fiscal 2nd quarter.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

CareFusion ChloraPrep sales make a resurgence following kickbacks scandal

May 7, 2014 by Arezu Sarvestani

CareFusion touts strong sales of its ChloraPrep antiseptic in the months following a $41 million settlement over past sales practices and relationships with healthcare professionals.

CareFusion marks $41M ChloraPrep settlement in Q3

California-based CareFusion (NYSE:CFN) posted a strong 3rd quarter and narrowed its full-year sales outlook, touting strong sales growth, even for its controversial ChloraPrep surgical wipes.